SOCS4 is a negative regulator of cytokine signaling that functions as the substrate-recognition component of an E3 ubiquitin-protein ligase complex 1. Through its SOCS box motif, SOCS4 mediates ubiquitination and proteasomal degradation of target proteins, inhibiting both EGF and JAK/STAT signaling pathways. Recent genome-wide CRISPR screens in iPSC-derived neurons identified CUL5-SOCS4 as a potent modifier of tau ubiquitination and proteostasis, with SOCS4 expression correlated with neuronal vulnerability to tauopathies including Alzheimer's disease and frontotemporal dementia 23. In cancer contexts, SOCS4 dysregulation exhibits cell-type-dependent effects: in renal and thyroid cancers, miRNA-mediated suppression of SOCS4 (via miR-9-5p and miR-25, respectively) promotes JAK/STAT pathway activation, facilitating proliferation and invasion 45. Conversely, SOCS4 upregulation in esophageal squamous cell carcinoma promotes progression through NF-κB signaling activation 6. In thyroid cancer, lncRNA ZNF674-AS1 suppresses malignancy by blocking miR-181a-mediated SOCS4 repression 7. These findings establish SOCS4 as a critical regulator of both neurodegenerative and neoplastic disease pathways, with therapeutic potential as a biomarker and intervention target.